Who is on the board of directors for CLINUVEL?
CLINUVEL’s Board of Directors comprises:
Mr. Stan McLiesh (Non-Executive Chair)
Dr. Philippe Wolgen (Managing Director, Chief Executive Officer),
Mrs. Brenda Shanahan (Non-Executive),
Dr Karen Agersborg (Non-Executive),
Mr. Willem Blijdorp (Non-Executive)
For full information, please see the CLINUVEL website.
Where is CLINUVEL headquartered?
CLINUVEL is headquartered in Melbourne, Australia with operations in Europe, the US and Singapore.
What is the focus of CLINUVEL’s business?
CLINUVEL PHARMACEUTICALS LTD is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe skin disorders.
As pioneers in understanding the interaction of light and human skin, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for PPT//RPT. These patient groups range in size from 5,000 to 45 million worldwide.
Where can I find historical data for CLINUVEL shares?
Historical data for CLINUVEL shares can be found on the Financial overview page on CLINUVEL’s webpage here.
How do I keep up to date with CLINUVEL’s latest developments?
CLINUVEL sends regular email updates on its progress, as well as published announcements and analyst reports. You can subscribe to this service here
How do I access or alter information about my existing shareholding?
CLINUVEL maintains its ASX shareholder registry with Computershare. ASX Shareholders are able to access the Company's share registry with Computershare online and view their Security Holdings (Account Details, Balances, Communication Details) and Shareholding Records. For all enquiries related to your ASX shareholding with CLINUVEL, contact:
Computershare Investor Services Pty Limited
GPO Box 2975
(Aus) 1300 555 159
(International) +61 (0)3 9415 4062
Within the US, CLINUVEL shares can be purchased in the US through the Bank of NY Mellon’s Level 1 American Depository Receipt (ADR) program under the ticket code CLVLY. Following the consolidation of the ASX listed CUV, CLVLY is now at a ratio of 1 ADR: 1 Ordinary Share of CUV. For more information on ADRs, log onto the Bank of NY Mellon’s ADR investors website here.
How do I invest in CLINUVEL?
CLINUVEL does not issue stock directly to investors. Please contact a financial advisor for more investing information.
Where is CLINUVEL’s stock listed?
CLINUVEL’s primary listing is on the Australian Securities Exchange under the ticker code CUV. A secondary listing is through the XETRA-DAX (Frankfurt) under the ticker code UR9.
The stock can also be purchased through a level 1 American Depository Receipt (ADR) with the symbol CLVLY. The ADR is part of the Nasdaq International Designation and facilitated by the Bank of New York Mellon.